Pomerantz LLP Opens Securities Fraud Investigation Into Erasca Over COO Termination

Pomerantz LLP is investigating claims on behalf of investors of Erasca, Inc. (NASDAQ: ERAS) over whether the company and certain officers or directors engaged in securities fraud or other unlawful business practices, the firm said in a PR Newswire release. Investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Erasca's October 16 Filing and the Stock Drop

Erasca disclosed in an October 16, 2026 filing with the U.S. Securities and Exchange Commission that "the employment of Nicholas (Nik) Chetwyn, Ph.D., the Company's Chief Operating Officer, will terminate effective November 2, 2026." Erasca attributed the termination to its decision "to realign its leadership responsibilities to support the development and potential commercialization of its RAS-targeting programs."

On that news, Erasca's stock price fell $1.48 per share, or 9.95%, to close at $13.39 per share on October 16, 2026. Pomerantz LLP is a plaintiff-side securities litigation law firm founded in 1936 that represents investors in securities class actions, corporate governance cases and global investor recovery proceedings across six offices in the U.S., U.K., France and Israel, according to akta.pro company records.

Pomerantz had already opened an investigation into Erasca on October 20, 2026, according to FinancialContent Business Page, which described the same October 16 filing and the same 9.95% decline to $13.39 per share. Erasca is the subject of a separate investigation announced by Grabar Law Office on October 26, 2026, alongside Aardvark Therapeutics, Power Solutions International and The Simply Good Foods Company, alleging securities fraud and fiduciary breaches, FinancialContent Business Page reported.

Pomerantz's Prior Investor Recoveries

The same records list historic recoveries Pomerantz achieved for investors: $3 billion in the Petrobras securities litigation, $350 million for United Healthcare investors and $225 million for Comverse Technology, Inc. investors. The firm maintains a global office network spanning New York, Chicago, Los Angeles, London, Paris and Tel Aviv.

Earlier Pomerantz Investor Actions

Pomerantz announced a proposed class action settlement for purchasers of Gritstone bio securities on September 28, 2026, with a $6 million settlement fund, a December 4, 2026 hearing and a November 13, 2026 claims deadline, PR Newswire reported. On September 1, 2026, the firm announced a class action lawsuit against Taboola.com Ltd. over alleged securities fraud, FinancialContent Business Page reported. Pomerantz filed a class action against Aardvark Therapeutics and its officers on August 21, 2026 over alleged securities fraud tied to the company's IPO and subsequent clinical trial data, FinancialContent Business Page reported.

Chetwyn's November 2 Departure

Erasca's October 16 filing set Chetwyn's termination effective November 2, 2026. The Gritstone bio settlement hearing is set for December 4, 2026, with claims due by November 13, 2026, PR Newswire reported.